Abstract
A 79-year-old man presented with gait dyspraxia approximately 2 days after receiving the first dose of the AstraZeneca COVID-19 vaccine (AZ-COVID-19-vax). He had no previous active issues and was currently on no medications.
Publisher
Peertechz Publications Private Limited
Reference5 articles.
1. 1. Medicines and Healthcare Products Regulatory Agency (MHRA). Regulatory approval of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) 2020 [updated 19 July, 2021. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca#history.
2. 2. Malhotra HS, Gupta P, Prabhu V, Kumar Garg R, Dandu H, Agarwal V. COVID-19 vaccination-associated myelitis. QJM. 2021 Nov 5;114(8):591-593. doi: 10.1093/qjmed/hcab069. PMID: 33787891; PMCID: PMC8083508.
3. 3. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021 Mar;9(3):251-259. doi: 10.1016/S2213-2600(20)30527-0. Epub 2020 Dec 17. PMID: 33341155; PMCID: PMC7832247.
4. 4. Department of Health. ATAGI statement regarding COVID-19 vaccines in the setting of transmission of the Delta variant of concern: Commonwealth of Australia; 2021. https://www.health.gov.au/news/atagi-statement-regarding-covid-19-vaccines-in-the-setting-of-transmission-of-the-delta-variant-of-concern.
5. 5. Cattaneo M. Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines. Eur J Intern Med. 2021 Jul;89:22-24. doi: 10.1016/j.ejim.2021.05.031. Epub 2021 May 25. PMID: 34092488; PMCID: PMC8148431.